Short answer
Teladoc Health, Inc. (TDOC) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded to ten directors with Mark V. Anquillare’s appointment effective August 3, 2026.
Teladoc Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to ten directors with Mark V. Anquillare’s appointment effective August 3, 2026
- Independent director under NYSE standards, supporting governance compliance
- Audit committee financial expert, strengthening financial oversight
- Added to audit and compensation committees, broadening oversight responsibilities
- Eligible for standard non-employee director compensation and indemnification arrangements
Item EX-99.1 · Exhibit EX-99.1
- Mark V. Anquillare appointed Teladoc director, adding over 30 years of financial and executive leadership experience
- Former Verisk CFO and COO, with experience leading its 2009 IPO and insurance-focused operations
- Audit and Compensation committee assignments strengthen financial oversight and executive-pay governance
- Board expertise in insurance, analytics, data, technology and AI aligns with Teladoc’s transformation strategy
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teladoc Health, Inc. 8-K filings
Get the next TDOC 8-K as it lands
Follow TDOC for push alerts, or ask the research agent what this filing means.